|
|
Neurology June 2009
Volume 72
Issue 23
| This Week in Neurology(R) |
this week in neurology(r): highlights of the june 9 issue.
Pages: 1971
|
| Editorial |
seeing injectable ms therapies differently symbol: they are more similar than different.
- Fox, Robert, Arnold, Douglas. Pages: 1972-1973
|
the learning curve for neuroendovascular procedures symbol: how important is it?
- Chaturvedi, Seemant, MD, FAHA, Dumont, Aaron. Pages: 1974-1975
|
| Articles |
efficacy of treatment of ms with ifn[beta]-1b or glatiramer acetate by monthly brain mri in the become study.
- Cadavid, D, Wolansky, L, Skurnick, J, Lincoln, J, Cheriyan, J, Szczepanowski, K, Kamin, S, Pachner, A, Halper, J, Cook, S. Pages: 1976-1983
>
Show/Hide Abstract
Background: There are no published MRI studies comparing interferon beta 1b (IFN[beta]-1b) and glatiramer acetate (GA) for treatment of relapsing multiple sclerosis (MS).Objective: To compare the efficacy of IFN[beta]-1b and GA for suppression of MS disease activity as evidenced on frequent brain MRI.Methods: A total of 75 patients with relapsing-remitting MS or clinically isolated syndromes were randomized to standard doses of IFN[beta]-1b or GA and followed by monthly brain MRI for up to 2 years with a protocol optimized to detect enhancement. The primary outcome was the number of combined active lesions (CAL) per patient per scan during the first year, which included all enhancing lesions and nonenhancing new T2/fluid-attenuated inversion recovery (FLAIR) lesions. Secondary outcomes were the number of new lesions and clinical exacerbations over 2 years.Results: Baseline characteristics were similar between the groups. The primary outcome showed similar median (75th percentile) CAL per patient per scan for months 1-12, 0.63 (2.76) for IFN[beta]-1b, and 0.58 (2.45) for GA (p = 0.58). There were no differences in new lesion or clinical relapses for 2 years. Only 4.4% of CAL on monthly MRI scans were nonenhancing new T2/FLAIR lesions.Conclusion: Patients with relapsing multiple sclerosis randomized to interferon beta 1b or glatiramer acetate showed similar MRI and clinical activity.(C)2009AAN Enterprises, Inc.
|
risk alleles for multiple sclerosis in multiplex families.
- D'Netto, M, Ward, H, Morrison, K, Ramagopalan, S, Dyment, D, DeLuca, G, Handunnetthi, L, Sadovnick, A, Ebers, G. Pages: 1984-1988
>
Show/Hide Abstract
Objective: We assessed the hypotheses that non-major histocompatibility complex multiple sclerosis (MS) susceptibility loci would be common to sporadic cases and multiplex families, that they would have larger effects in multiplex families, and that the aggregation of susceptibility loci contributes to the increased prevalence of MS in such families.Methods: A set of 43 multiplex families comprising 732 individuals and 211 affected subjects was genotyped for 13 MS candidate genes identified by genome-wide association. A control data set of 182 healthy individuals was also genotyped to perform a case-control analysis alongside the family-based pedigree disequilibrium association test, although this may have been underpowered.Results: An effect of the IL2RA and CD58 loci was shown in multiplex families as in sporadic MS. The aggregate of the IL2RA, IL7R, EVI5, KIAA0350, and CD58 risk genotypes in affected individuals from multiplex families was found to be notably different from controls ([chi]2 = 112, p = 1 x 10-22).Conclusions: Although differences between individual families can only be suggested, the aggregate results in multiplex families demonstrate effect sizes that are increased as compared with those reported in previous studies for sporadic cases. In addition, they imply that concentrations of susceptibility alleles at IL2RA, IL7R, EVI5, KIAA0350, and CD58 are partly responsible for the heightened prevalence of multiple sclerosis within multiplex families.(C)2009AAN Enterprises, Inc.
|
effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
- Rudick, R, Pace, A, Rani, M, Hyde, R, Panzara, M, Appachi, S, Shrock, J, Maurer, S, Calabresi, P, Confavreux, C, Galetta, S, Lublin, F, Radue, E, Ransohoff, R. Pages: 1989-1993
>
Show/Hide Abstract
Background: Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFN[beta]) in patients with relapsing-remitting multiple sclerosis (RRMS).Methods: We conducted a post hoc analysis of data from the Safety and Efficacy of Natalizumab in Combination With IFN[beta]-1a in Patients With Relapsing-Remitting Multiple Sclerosis (SENTINEL) study to determine the effects of statins on efficacy of IFN[beta]. SENTINEL was a prospective trial of patients with RRMS treated with natalizumab (Tysabri(R), Biogen Idec, Inc., Cambridge, MA) plus IM IFN[beta]-1a (Avonex(R), Biogen Idec, Inc.) 30 [mu]g compared with placebo plus IM IFN[beta]-1a 30 [mu]g. Clinical and MRI outcomes in patients treated with IM IFN[beta]-1a only (no-statins group, n = 542) were compared with those of patients taking IM IFN[beta]-1a and statins at doses used to treat hyperlipidemia (statins group, n = 40).Results: No significant differences were observed between treatment groups in adjusted annualized relapse rate (p = 0.937), disability progression (p = 0.438), number of gadolinium-enhancing lesions (p = 0.604), or number of new or enlarging T2-hyperintense lesions (p = 0.802) at 2 years. More patients in the statins group reported fatigue, extremity pain, muscle aches, and increases in hepatic transaminases compared with patients in the no-statins group. Statin treatment had no ex vivo or in vitro effect on induction of IFN-stimulated genes.Conclusions: Statin therapy does not appear to affect clinical effects of IM interferon beta-1a in patients with relapsing-remitting multiple sclerosis or the primary molecular response to interferon beta treatment.(C)2009AAN Enterprises, Inc.
|
mri lesion profiles in sporadic creutzfeldt-jakob disease.
- Meissner, B, Kallenberg, K, Sanchez-Juan, P, Collie, D, Summers, D, Almonti, S, Collins, S, Smith, P, Cras, P, Jansen, G, Brandel, J, Coulthart, M, Roberts, H, Van Everbroeck, B, Galanaud, D, Mellina, V, Will, R, Zerr, I. Pages: 1994-2001
>
Show/Hide Abstract
Background: With respect to sporadic Creutzfeldt-Jakob disease (sCJD), six molecular subtypes (MM1, MM2, MV1, MV2, VV1, and VV2) have been described, which vary with respect to age at disease onset, disease duration, early symptoms, and neuropathology. MRI signal alterations were reported to correlate with distinct Creutzfeldt-Jakob disease (CJD) subtypes. This multicenter, international study aimed to describe the brain MRI findings associated with each of the sCJD molecular subtypes.Methods: Pathologically confirmed sCJD cases with codon 129 genotype (MM, MV, and VV), PrPSc type, and fluid-attenuated inversion recovery (FLAIR) or diffusion-weighted imaging (DWI) were collected in seven countries. All MRI scans were assessed for signal changes according to a standard protocol encompassing seven cortical regions, basal ganglia, thalamus, and cerebellum.Results: MRI scans were evaluated in 211 CJD patients (98 MM1, 23 MM2, 19 MV1, 30 MV2, 9 VV1, and 32 VV2). Basal ganglia hyperintensities occurred most frequently in MV2, VV2, and MM1 subtypes (79, 77, and 70%). Wide cerebral cortical signal increase was most common in VV1, MM2, and MV1 subtypes (86, 77, and 77%). Thalamic hyperintensities occurred most often in VV2 (45%) and MV2 (43%). The most consistent finding across most subtypes was high signal in basal ganglia, with these abnormalities found in 63% (FLAIR) and 71% (DWI).Conclusion: Cortical signal increase and hyperintensities in the basal ganglia and thalamus are detected by MRI across all molecular sporadic Creutzfeldt-Jakob disease subtypes. Our findings argue that characteristic MRI lesion patterns may occur for each molecular subtype.(C)2009AAN Enterprises, Inc.
|
efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy.
- Iodice, V, Kimpinski, K, MD, PhD, Vernino, S, MD, PhD, Sandroni, P, MD, PhD, Fealey, R, Low, P. Pages: 2002-2008
>
Show/Hide Abstract
Objective: To evaluate the efficacy of immunotherapy in the treatment of patients with seropositive and seronegative putative autoimmune autonomic ganglionopathy (AAG) using validated autonomic function tests and instruments.Background: AAG is an immune-mediated disorder characterized by prominent and selective involvement of autonomic nerve fibers or ganglia. Treatment with IV immunoglobulin (IVIg) or plasma exchange (PE) has been reported to be effective in single case reports.Methods: We studied six patients, four with seropositive and two with seronegative putative AAG, who underwent autonomic function tests and completed two validated questionnaires, to assess autonomic symptoms before and after immunomodulatory treatment. Patients were treated with standard doses of IVIg, PE, or immunosuppressants in a specific sequential therapy protocol depending on clinical response.Results: Of the six patients (all women, mean ages 49.3 +/- 10.6 years), four patients were ganglionic ([alpha]3) AChR autoantibody positive and two were autoantibody negative. All patients showed clinical improvement after treatment. Sudomotor function assessed by quantitative sudomotor axon reflex test and thermoregulatory sweat test improved in four patients after treatment.Conclusions: Immunomodulatory treatment can be effective in both seropositive and seronegative putative autoimmune autonomic ganglionopathy. Plasma exchange or combined therapy with immunosuppressive agents should be considered in patients who do not benefit from IV immunoglobulin alone.(C)2009AAN Enterprises, Inc.
|
deficient high-acceleration vestibular function in patients with polyneuropathy.
- Palla, A, Schmid-Priscoveanu, A, Studer, A, Hess, K, Straumann, D. Pages: 2009-2013
>
Show/Hide Abstract
Background: Unsteadiness during standing and walking is a frequent complaint of patients with polyneuropathy (PNP).Objective: To determine whether balance disorders in patients with PNP may be caused by reduced proprioceptive input from the feet alone or whether impaired vestibular input, resulting from involvement of the vestibular nerve, can be an additional factor.Methods: A total of 37 patients (mean age 65 years +/- 12 SD; 12 women) with electrodiagnostically confirmed PNP (predominantly axonal: 18; predominantly demyelinating: 19) underwent horizontal search-coil head-impulse testing, which assesses the high-acceleration vestibulo-ocular reflex (VOR).Results: Relative to a healthy comparison group, the gains (eye velocity divided by head velocity) of the horizontal VOR were reduced in 27 of 37 patients (unilateral: 13; bilateral: 14). The percentages of patients with unilateral or bilateral VOR deficits were not significantly different between patients with axonal or demyelinating PNP.Conclusions: Two thirds of patients with axonal or demyelinating polyneuropathy (PNP) showed unilateral (~50%) or bilateral (~50%) gain reductions of the horizontal high-acceleration vestibulo-ocular reflex. This finding suggests that, in many patients with PNP, the neuropathic process includes the vestibular nerve. Such information is highly relevant for subsequent physical therapy, since vestibular exercise improves balance control and reduces disability.(C)2009AAN Enterprises, Inc.
|
risk factors associated with major cerebrovascular complications after intracranial stenting .
- Nahab, F, Lynn, M, Kasner, S, Alexander, M, MD, FACS, Klucznik, R, Zaidat, O, Chaloupka, J, Lutsep, H, Barnwell, S, Mawad, M, Lane, B, BSN, RN, Chimowitz, M, MB, ChB. Pages: 2014-2019
>
Show/Hide Abstract
Background: There are limited data on the relationship between patient and site characteristics and clinical outcomes after intracranial stenting.Methods: We performed a multivariable analysis that correlated patient and site characteristics with the occurrence of the primary endpoint (any stroke or death within 30 days of stenting or stroke in the territory of the stented artery beyond 30 days) in 160 patients enrolled in this stenting registry. All patients presented with an ischemic stroke, TIA, or other cerebral ischemic event (e.g., vertebrobasilar insufficiency) in the territory of a suspected 50-99% stenosis of a major intracranial artery while on antithrombotic therapy.Results: Cerebral angiography confirmed that 99% (158/160) of patients had a 50-99% stenosis. In multivariable analysis, the primary endpoint was associated with posterior circulation stenosis (vs anterior circulation) (hazard ratio [HR] 3.4, 95% confidence interval [CI] 1.2-9.3, p = 0.018), stenting at low enrollment sites (<10 patients each) (vs high enrollment site) (HR 2.8, 95% CI 1.1-7.6, p = 0.038), <=10 days from qualifying event to stenting (vs >=10 days) (HR 2.7, 95% CI 1.0-7.8, p = 0.058), and stroke as a qualifying event (vs TIA/other) (HR 3.2, 95% CI 0.9-11.2, p = 0.064). There was no significant difference in the primary endpoint based on age, gender, race, or percent stenosis (50-69% vs 70-99%).Conclusions: Major cerebrovascular complications after intracranial stenting may be associated with posterior circulation stenosis, low volume sites, stenting soon after a qualifying event, and stroke as the qualifying event. These factors will need to be monitored in future trials of intracranial stenting.(C)2009AAN Enterprises, Inc.
|
the essential neurologic examination: what should medical students be taught?
- Moore, Fraser, MD, FRCPC, Chalk, Colin, MDCM, FRCPC. Pages: 2020-2023
>
Show/Hide Abstract
Background: Graduating medical students often identify the neurologic examination (NE) as one of the clinical skills with which they are least comfortable. We hypothesized that this is because they are unsure about which elements of the NE are important, and conducted a study 1) to identify whether neurologists agree about the essential elements of the NE and 2) to determine whether the views of medical students about what is essential differ from those of neurologists.Methods: Using a Delphi process, we asked McGill University neurologists which elements of the NE they would perform at least 80% of the time in a common clinical scenario. We confirmed the results in a sample of Canadian neurologists, and then compared the results of the McGill neurologists to a sample of graduating McGill University medical students.Results: The neurologists surveyed rated 22 items of the NE as essential, and there was a high degree of consensus about which items were essential. Medical student ratings of the importance of NE items were largely similar to those of the neurologists, although there were some noteworthy discrepancies.Conclusions: The anxiety felt by medical students regarding the neurologic examination (NE) seems unlikely to be solely due to uncertainty about which elements of the NE are important. Expert consensus about the essential elements of the NE and awareness of areas where neurologist and student views differ should be used to guide teaching of the NE.(C)2009AAN Enterprises, Inc.
|
characterization of dctn1 genetic variability in neurodegeneration.
- Vilarino-Guell, C, Wider, C, Soto-Ortolaza, A, Cobb, S, Kachergus, J, Keeling, B, Dachsel, J, Hulihan, M, Dickson, D, Wszolek, Z, Uitti, R, Graff-Radford, N, Boeve, B, Josephs, K, Miller, B, Boylan, K, Gwinn, K, Adler, C, Aasly, J, Hentati, F, Destee, A, Krygowska-Wajs, A, Chartier-Harlin, M, Ross, O, Rademakers, R, Farrer, M. Pages: 2024-2028
>
Show/Hide Abstract
Objective: Recently, mutations in DCTN1 were found to cause Perry syndrome, a parkinsonian disorder with TDP-43-positive pathology. Previously, mutations in DCTN1 were identified in a family with lower motor neuron disease, in amyotrophic lateral sclerosis (ALS), and in a family with ALS/frontotemporal dementia (FTD), suggesting a central role for DCTN1 in neurodegeneration.Methods: In this study we sequenced all DCTN1 exons and exon-intron boundaries in 286 samples diagnosed with Parkinson disease (PD), frontotemporal lobar degeneration (FTLD), or ALS.Results: This analysis revealed 36 novel variants (9 missense, 5 silent, and 22 noncoding). Segregation analysis in families and association studies in PD, FTLD, and ALS case-control series did not identify any variants segregating with disease or associated with increased disease risk.Conclusions: This study suggests that pathogenic mutations in DCTN1 are rare and do not play a common role in the development of Parkinson disease, frontotemporal lobar degeneration, or amyotrophic lateral sclerosis.(C)2009AAN Enterprises, Inc.
|
predictors of maintaining cognitive function in older adults: the health abc study.
- Yaffe, K, Fiocco, A, Lindquist, K, Vittinghoff, E, Simonsick, E, Newman, A, Satterfield, S, Rosano, C, Rubin, S, Ayonayon, H, Harris, T. Pages: 2029-2035
>
Show/Hide Abstract
Background: Although several risk factors for cognitive decline have been identified, much less is known about factors that predict maintenance of cognitive function in advanced age.Methods: We studied 2,509 well-functioning black and white elders enrolled in a prospective study. Cognitive function was measured using the Modified Mini-Mental State Examination at baseline and years 3, 5, and 8. Random effects models were used to classify participants as cognitive maintainers (cognitive change slope >=0), minor decliners (slope <0 and >1 SD below mean), or major decliners (slope <=1 SD below mean). Logistic regression was used to identify domain-specific factors associated with being a maintainer vs a minor decliner.Results: Over 8 years, 30% of the participants maintained cognitive function, 53% showed minor decline, and 16% had major cognitive decline. In the multivariate model, baseline variables significantly associated with being a maintainer vs a minor decliner were age (odds ratio [OR] = 0.65, 95% confidence interval [CI] 0.55-0.77 per 5 years), white race (OR = 1.72, 95% CI 1.30-2.28), high school education level or greater (OR = 2.75, 95% CI 1.78-4.26), ninth grade literacy level or greater (OR = 4.85, 95% CI 3.00-7.87), weekly moderate/vigorous exercise (OR = 1.31, 95% CI 1.06-1.62), and not smoking (OR = 1.84, 95% CI 1.14-2.97). Variables associated with major cognitive decline compared to minor cognitive decline are reported.Conclusion: Elders who maintain cognitive function have a unique profile that differentiates them from those with minor decline. Importantly, some of these factors are modifiable and thus may be implemented in prevention programs to promote successful cognitive aging. Further, factors associated with maintenance may differ from factors associated with major cognitive decline, which may impact prevention vs treatment strategies.(C)2009AAN Enterprises, Inc.
|
| Neurology Clinical Pathological Conference |
a 49-year-old man with contractures, weakness, and cardiac arrhythmia.
- Kissel, J, Dimberg, E, Emslie-Smith, A, MD, PhD, Selcen, D, Keegan, B, MD, FRCPC. Pages: 2036-2043
|
| Clinical/Scientific Notes |
multiple dural lesions mimicking meningiomas in patients with ccm3/pdcd10 mutations.
- Labauge, P, Fontaine, B, MD, PhD, Neau, J, Bergametti, F, Riant, F, Blecon, A, Marchelli, F, Arnoult, M, Lannuzel, A, MD, PhD, Clanet, M, Olschwang, S, Denier, C, MD, PhD, Tournier-Lasserve, E. Pages: 2044-2046
|
cerebellar signs in celiac disease.
- Versino, M, Franciotta, D, Colnaghi, S, Biagi, F, Zardini, E, Bianchi, P, Corazza, G, Cosi, V. Pages: 2046-2048
|
| Reflections: Neurology And The Humanities |
teaching rounds and change.
- Ringel, Steven. Pages: 2049-2051
|
| Resident & Fellow Section |
pearls & oy-sters: hyperdense or pseudohyperdense mca sign: a damocles sword?
- Jha, Bhawna, MD, MRCPsych, Kothari, Milind. Pages: e116-e117
|
teaching video neuroimages: paroxysmal kinesigenic dyskinesia.
- Borchert, Alexandra, Moddel, Gabriel, Schilling, Matthias. Pages: e118
|
| Correspondence |
network atrophy in temporal lobe epilepsy: a voxel-based morphometry study.
- Bonilha, Leonardo, Halford, Jonathan. Pages: 2052
|
hepatitis b vaccine and the risk of cns inflammatory demyelination in childhood.
- Braillon, Alain, Dubois, Gerard. Pages: 2053
|
the placebo treatments in neurosciences: new insights from clinical and neuroimaging studies.
- Oken, Barry. Pages: 2053-2054
|
the abpn maintenance of certification program for neurologists: past, present, and future.
- Snyder, Bruce. Pages: 2054
|
topiramate in pregnancy: preliminary experience from the uk epilepsy and pregnancy register.
- Martinez-Frias, Maria-Luisa. Pages: 2054-2055
|
motor cortex stimulation for chronic pain: systematic review and meta-analysis of the literature.
- Landau, William, Thach, W. Pages: 2055-2056
|
burden of atherosclerosis and risk of venous thromboembolism in patients with migraine.
- Sacco, Simona, Carolei, Antonio. Pages: 2056-2057
|
natural history of sma iiib: muscle strength decreases in a predictable sequence and magnitude.
- Piepers, S, van der Pol, W, Brugman, F, Wokke, J, van den Berg, L. Pages: 2057-2058
|
| Correction |
high-resolution diffusion tensor imaging in the substantia nigra of de novo parkinson disease.
Pages: 2059
|
| Departments: Calendar |
calendar.
Pages: 2060
|
| Future Issues |
in the next issue of neurology(r): volume 72, number 24, june 16, 2009.
Pages: A38
|
|
Advertisement
|